Recommended reading: Adult Non-Hodgkin Lymphoma Treatment (PDQ®): Patient Version
PubMed Health. A service of the National Library of Medicine, National Institutes of Health.
A.D.A.M. Medical Encyclopedia [Internet]. Atlanta (GA): A.D.A.M.; 2013.
A.D.A.M. Medical Encyclopedia.
Non-Hodgkin lymphoma (NHL) is cancer of the lymph tissue. Lymph tissue is found in the lymph nodes, spleen, and other organs of the immune system.
White blood cells called lymphocytes are found in lymph tissue. They help prevent infections. Most lymphomas start in a type of white blood cell called B lymphocyte, or B cell.
Causes, incidence, and risk factors
For most patients, the cause of NHL is unknown. But lymphomas may develop in people with weakened immune systems, including persons who have had an organ transplant or persons with HIV infection.
NHL most often affects adults. Men get NHL more often than women. Children can get some forms of lymphoma.
There are many types of NHL. Specific types are grouped according to how fast the cancer spreads. The cancer may be low grade (slow growing), intermediate grade, or high grade (fast growing).
The cancer is further grouped by how the cells look under the microscope, what type of white blood cell it originates from, and whether there are certain DNA changes.
Symptoms
Symptoms depend on what area of the body is affected by the cancer and how fast the cancer is growing.
Symptoms may include:
- Night sweats (soaking the bedsheets and pajamas even though the room temperature is not too hot)
- Fever and chills that come and go
- Itching
- Swollen lymph nodes in the neck, underarms, groin, or other areas
- Weight loss
- Coughing or shortness of breath if the cancer affects the thymus gland or lymph nodes in the chest, putting pressure on the windpipe (trachea) or other airways
- Abdominal pain or swelling, leading to loss of appetite, constipation, nausea, and vomiting
- Headache, concentration problems, personality changes, or seizures if the cancer affects the brain
Signs and tests
The doctor will perform a physical exam and check body areas with lymph nodes to feel if they are swollen.
The disease may be diagnosed after biopsy of suspected tissue, usually a lymph node biopsy.
Other tests that may be done include:
- Blood test to check protein levels, liver function, kidney function, and uric acid level
- Complete blood count (CBC)
- CT scans of the chest, abdomen and pelvis
- PET (positron emission tomography) scan
If tests show you have NHL, more tests will be done to see how far it has spread. This is called staging. Staging helps guide future treatment and follow-up. It also gives you an idea of what to expect in the future.
Treatment
Treatment depends on:
- The type of lymphoma
- The stage when you are first diagnosed
- Your age and overall health
- Symptoms, including weight loss, fever, and night sweats
You may receive chemotherapy, radiation therapy, or both. Or you may not need treatment. Your doctor can tell you more about your specific treatment.
Radioimmunotherapy may be used in some cases. This involves linking a radioactive substance to an antibody that targets the cancerous cells and injecting the substance into the body.
High-dose chemotherapy may be given when NHL returns after treatment or does not respond to the first treatment. This is followed by an autologous stem cell transplant (using your own stem cells).
Blood transfusions or platelet transfusions may be required if blood counts are low.
Support Groups
You can ease the stress of illness by joining a cancer support group. Sharing with others who have common experiences and problems can help you not feel alone.
Expectations (prognosis)
Low-grade NHL usually cannot be cured by chemotherapy alone. Low-grade NHL progresses slowly and it may take many years before the disease gets worse or even requires treatment.
Chemotherapy can often cure many types of high-grade lymphomas. If the cancer does not respond to chemotherapy, the disease can cause rapid death.
Complications
NHL itself and its treatments can lead to health problems. These include:
- Autoimmune hemolytic anemia
- Infection
- Side effects of chemotherapy drugs
Keep following up with a doctor who knows about monitoring and preventing these complications.
Calling your health care provider
Call your health care provider if you develop symptoms of this disorder.
If you have NHL, call your health care provider if you experience persistent fever or other signs of infection.
References
- National Cancer Institute: PDQ Adult Non-Hodgkin Lymphoma Treatment. Bethesda, MD: National Cancer Institute. Date last modified 09/28/2012. Available at http://www.cancer.gov/cancertopics/pdq/treatment/adult-non-hodgkins/HealthProfessional. Accessed 01/04/2013.
- National Cancer Institute: PDQ Childhood Non-Hodgkin Lymphoma Treatment. Bethesda, MD: National Cancer Institute. Date last modified 11/26/2012. Available at http://cancer.gov/cancertopics/pdq/treatment/child-non-hodgkins/HealthProfessional. Accessed 01/04/2013.
- National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Non-Hodgkin’s Lymphomas. Version 1.2013. Available at http://www.nccn.org/professionals/physician_gls/pdf/nhl.pdf. Accessed 01/04/2013.
- Wilson WH, Armitage JO. Non-Hodgkin’s lymphoma. In: Abeloff MD, Armitage JO, Niederhuber JE, et al., eds. Clinical Oncology. 4th ed. Philadelphia, PA: Elsevier Churchill-Livingstone; 2008:chap 112.
Review Date: 2/8/2013.
Reviewed by: Yi-Bin Chen, MD, Leukemia/Bone Marrow Transplant Program, Massachusetts General Hospital. Also reviewed by A.D.A.M. Health Solutions, Ebix, Inc., Editorial Team: David Zieve, MD, MHA, Bethanne Blackman, Stephanie Slon, and Nissi Wang.
A.D.A.M., Inc. is accredited by URAC, also known as the American Accreditation HealthCare Commission (www.urac.org). URAC's accreditation program is an independent audit to verify that A.D.A.M. follows rigorous standards of quality and accountability. A.D.A.M. is among the first to achieve this important distinction for online health information and services. Learn more about A.D.A.M.'s editorial policy, editorial process and privacy policy. A.D.A.M. is also a founding member of Hi-Ethics and subscribes to the principles of the Health on the Net Foundation (www.hon.ch).
The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions. Call 911 for all medical emergencies. Links to other sites are provided for information only — they do not constitute endorsementscof those other sites. © 1997–2011 A.D.A.M., Inc. Any duplication or distribution of the information contained herein is strictly prohibited.
The role of chemotherapy additional to high‐dose methotrexate for treatment of patients with primary central nervous system lymphoma
Primary central nervous system lymphoma (PCNSL) is a malignant disease of the lymphatic system that accounts for about 2% to 5% of all primary intracranial tumours in immunocompetent patients. It is a form of extranodal non‐Hodgkin lymphoma (NHL) and appears at a median age of 62 years. PCNSL is a rare disease with an incidence of 2.7 cases per million population per year, but since the 1990s the occurrence of it has increased in immunocompetent as well as immunocompromised (mostly human immunodeficiency virus (HIV)‐infection related) populations. Symptoms of PCNSL can present manifold though the usual signs are neurological deficits, neuropsychiatric symptoms and raised intracranial pressure. Despite improved treatment strategies, overall survival is still poor and a standard of care for PCNSL patients has not been defined yet. However, high‐dose methotrexate (HD‐MTX) with additional chemotherapy is considered to increase overall survival although the value of additional chemotherapy remains unclear, as there is evidence of a higher risk of adverse events. In this systematic review we summarised and analysed the evidence from randomised controlled trials (RCTs) on efficacy and safety of methotrexate combined with additional chemotherapy in the treatment of adult, immunocompetent PCNSL patients regarding overall survival, progression‐free survival, response rate, adverse events, treatment‐related mortality and quality of life. We searched several important medical databases such as CENTRAL and MEDLINE and found one RCT with 79 patients that fulfilled our inclusion criteria. As a result, this review shows that patients treated with methotrexate plus cytarabine compared to high‐dose methotrexate alone have a statistically significant improvement in progression‐free survival and response rate. No statistically significant difference is shown for overall survival. Adverse events, especially infections, hepatotoxicity and haematological toxicities are more common in patients undergoing therapy with methotrexate plus cytarabine, although there are no differences in terms of treatment‐related mortality. Owing to the small number of included trials and patients, the findings in this review remain uncertain and more RCTs with enlarged numbers of patients and longer follow‐up periods are needed. However, the one analysed study demonstrated that RCTs are feasible on patients with this rare disease and should concentrate on overall survival.
Making smart health choicesDevelop the skills to assess health advice and make better-informed decisions about your health and managing illness.
- Non-Hodgkin lymphomaNon-Hodgkin lymphomaPubMed Health
Your browsing activity is empty.
Activity recording is turned off.
See more...
